Research

Cellular

The goal of management in T2D patients with significant fibrosis is to slow the progression of liver disease and reduce associated clinical events.

Clinicians should aim to adapt therapies to manage liver disease progression in diabetic patients.

StrongSupportsmedium confidence
Our goal is to provide clinical guidance for adapting drug therapy in the presence of significant fibrosis in order to slow the progression of liver disease and reduce the risk of associated clinical events.
Yasmina Chouik et al. · Diabetes & Metabolism · 2025

Why this rating

The claim is based on expert consensus and clinical guidance.

Source

Management of patients with type 2 diabetes and MASLD: An overview and joint statement

Yasmina Chouik et al. · Diabetes & Metabolism · 2025

DOI 10.1016/j.diabet.2025.101709

reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →